about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibState of the art biological therapies in pancreatic cancerAdjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysisPersonalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisGenetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapiesSDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing.Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutationsPreclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.Three cases of bone metastases in patients with gastrointestinal stromal tumors.Neoadjuvant treatment in rectal cancer: actual status.Efficacy of weekly docetaxel in locally advanced cardiac angiosarcomaSDHC methylation in gastrointestinal stromal tumors (GIST): a case report.Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cellsPolymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Preoperative gemcitabine and oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinomaMolecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis.Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses.Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma PatientsLaparoscopic treatment of gastric GIST: report of 21 cases and literature's review.Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives.Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey.Gastrointestinal stromal tumors: report of an audit and review of the literature.Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression.Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.
P50
Q21261282-3D0A954C-D950-4FF6-A798-C5EA84900D9DQ26769941-AF1CA21D-CB89-4177-A93B-4A6A05CB4B8AQ26774704-8CA0F010-5CEC-43C4-BFB4-A9B34C1A81EFQ26800005-515C9DEB-5CA0-47AE-A138-08D690D136EFQ26852049-F786E3F4-1B63-4498-AF97-F5BB8F0117ECQ30401988-3EAA1BE2-5305-497A-8BE0-E1368533CDC6Q33420123-11F0683A-4C47-4AD9-B7CF-841EB33AB293Q33722723-48EC1FEA-5F86-4CF7-BD37-0433BD1AC7EBQ34141825-DCE92531-9C24-4FC2-AAC1-334527813EF5Q34274467-3B9EA2B3-6531-4B7F-BAB1-A060F8C6E108Q34387843-AB265F81-118B-4222-8A50-D88A59E19DFBQ34499075-EC517DB9-67BA-4AE6-ADF4-317ED19B44DBQ34629408-1C1ED722-7903-4643-B10D-DCEA9A458ACBQ35093218-A82D1BA5-FA03-410D-9811-D219E7C1F949Q35687452-22E46D25-0310-4942-A574-7C0B71FB17C3Q35724800-5DAEF7C6-85AB-43F9-899F-3F959E12D6D0Q35790835-09C642AA-8E25-48C8-85CF-FF6B160FCE19Q35831238-59F999BF-AE68-4175-9CCE-F31A219E8C83Q35893413-4AD36140-5D00-437B-B055-0506CD8C376BQ36086354-F063360D-2B1D-4F8F-B6F2-C31F02FD9993Q36206173-7006809C-3957-44DD-91DE-5125357AB9FAQ36561734-C2ABB8AE-41C2-462C-B57C-5CF527F95EB3Q36695209-8BA9E1E3-877A-4E0D-A916-69BC7F2EFFEBQ36780461-AE7BED59-6613-4782-BE68-DBEE7874DCEAQ36825910-99447347-DB9A-4990-B61F-EF3E4DE88C84Q36884377-B420538A-1C92-4D80-A460-133606004883Q37015334-DB7509D3-15D6-43AC-8A98-3188968103FCQ37350278-BE2029B6-B354-4154-9A07-CF4CC9C0190DQ37397647-AE74E882-A672-4620-AA04-CDE53562A6C8Q37404372-B73A9D37-D7ED-4A59-9E94-41D7D0C7C79DQ37427924-977DED87-AED5-4490-8159-CB572F94E8FCQ37428518-42B52505-1D83-4771-97A9-32E45464061DQ37474435-E5B6C4AF-D178-431E-9AA5-C76D5D7DE1C8Q37633233-5D550E64-CE0B-4094-BDEB-7AE67E65FDD7Q37688851-1AF571E2-3BB9-43D1-885D-8023A7266866Q37725694-41A3BC2F-15E4-47E5-A554-F03E4F3DCDBAQ37850810-9D96E08F-BD93-4404-8197-AA8803885D6BQ38119931-F24662E3-6C30-4678-AABC-0EE5B83B285FQ38152981-317F21D0-648E-445B-BE83-102BAEB89F70Q38268165-CEC39512-8E3D-46FB-B476-7EFC98652202
P50
name
Guido Biasco
@en
type
label
Guido Biasco
@en
prefLabel
Guido Biasco
@en